XELTIS
2.12.2014 13:01:41 CET | Business Wire | Pressemeddelelse
Xeltis , a privately-held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has raised EURO 27 million (USD 34 million/CHF 32 million) in an oversubscribed Series B financing. Life Sciences Partners, Amsterdam (LSP) and Kurma Partners, Paris (Kurma) led the round, with participation from VI Partners, Zug (VI) and current shareholders of Xeltis. The financing will primarily be used to fund market access activities for the company’s first product, a pulmonary valve, and the development of the company’s product pipeline. The replacement pulmonary valve will be used to treat the orphan pediatric indication of severe congenital malformations of the heart.
Xeltis is developing synthetic biodegradable heart valves and blood vessels (“matrices”), enabling a completely new therapeutic category called Endogenous Tissue Growth (“ETG”). Xeltis’ proprietary technology, based on Nobel prize-winning science, is designed to stimulate and guide the body’s natural healing response from the inside, leading to spontaneous growth of new valves and vessels within the body, once the matrices are implanted. The matrices are intended to biodegrade as natural tissue grows, leaving no foreign material behind. Xeltis holds the promise to enable ETG for the first time.
“We believe that Xeltis has the potential to bring a complete paradigm shift in cardiac and vascular surgery,” said Clemens van Blitterswijk, partner at LSP. “The uniqueness and the breakthrough nature of their technology make Xeltis a very attractive investment opportunity“. Vanessa Malier, partner at Kurma, added: “We were impressed by the broad potential of Xeltis’ breakthrough technology and by the team’s achievements in turning it into game-changing products in cardiology and surgery. Xeltis’ first product will target rare cardiac malformations affecting children. This investment fits perfectly with our fund strategy and we are excited to support the development of the company.”
“This investment marks a significant milestone for Xeltis. Having preeminent investment firms join forces with us gives us the means to fulfill our ambitious objective, which is to improve the lives of millions of patients”, said Laurent Grandidier, Chief Executive Officer. “Our ongoing clinical studies and our extensive pre-clinical testing have created a solid foundation of evidence supporting the feasibility, safety and versatility of our technology. This financing speaks to the tremendous clinical value Xeltis is anticipated to provide to patients and physicians.”
About Endogenous Tissue Growth
Endogenous Tissue Growth (ETG) is a therapeutic category in which surgeons use synthetic biodegradable implants designed to allow the body to repair itself by spontaneously growing natural, healthy tissue from the inside. Because the tissue produced through ETG is the patient’s own, the treatment has the potential to overcome the limitations of current standard of care. No foreign material is permanently implanted in the body, so long-term medication may no longer be needed. In addition, the risk of repeated surgeries may be reduced.
For more information, visit http://www.xeltis.com
About Life Sciences Partners - For information, visit http://www.lspvc.com
About Kurma Partners - For information, visit http://www.kls-partners.com/
About VI Partners – For information, visit http://www.vipartners.ch
CAUTION: INVESTIGATIONAL DEVICE.
No. No. No.
German and French versions of this release available at http://www.xeltis.com/media-kit/
Contact:
Genevensis Healthcare Communications
Danièle A. Castle
Email: daniele.castle@genevensis.com
Tel:
+ 41 79 202 6667
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
The Estée Lauder Companies Announces Partnership with Profound to Expand AI Visibility Across Its Global Brand Portfolio14.9.2026 18:32:00 CEST | Press release
Partnership enables the company to lead prestige beauty's transition to AI-powered discovery while better understanding how consumers discover, evaluate, and engage with its brands across AI answer engines The Estée Lauder Companies Inc. (NYSE: EL) today announced a global strategic partnership with Profound, the category-defining AI marketing platform, advancing its ambition to be prestige beauty’s leader in AI-native discovery. The partnership will provide the company with visibility into how its full portfolio of brands is represented across leading generative AI platforms, as well as opportunities to optimize that representation. This partnership establishes the company as the first in prestige beauty to deploy Profound’s capabilities globally across the company’s full portfolio and operationalize Generative Engine Optimization (GEO) and AI marketing at scale. As consumers increasingly turn to ChatGPT, Gemini, and other AI assistants to discover products, compare recommendations, a
AMAALA Yacht Club Opens, Putting the Red Sea on the Global Yachting Map14.9.2026 18:00:00 CEST | Press release
Luxury sailing, wellness and exploration converge at Saudi Arabia's newest yachting destination Red Sea Global (RSG), the regenerative tourism developer, has announced that AMAALA Yacht Club has officially begun operations, marking a major milestone in establishing the Saudi Red Sea as a new global destination for luxury yachting, sailing and marine tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914160771/en/ AMAALA Yacht Club, the new luxury yachting destination on Saudi Arabia’s Red Sea coast. Nestled within AMAALA Marina Village, the AMAALA Yacht Club is now welcoming founding members and visiting yachts to moor and explore the destination. Located approximately 2,000 nautical miles from Monaco, the club provides a new winter destination for the world’s luxury sailing community, which traditionally migrates from the Mediterranean to the Caribbean or Indian Ocean from October. Positioned closer to the Mediterra
Behind the Stage Lights: How Students Learned to Trust Their Voices with Doha Debates14.9.2026 15:40:00 CEST | Press release
During high school years in Model United Nations, Dahlia Al-Ansari learned to argue on behalf of a country she was assigned to represent. But when Doha Debates invited her to join a town hall debate in Toronto this July, she faced an unfamiliar challenge: sharing her own beliefs about a timely issue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914150232/en/ Students from Qatar, Canada and Mexico during their visit to the University of Toronto as part of the Doha Debates Town Hall experience in Canada. (Photo: AETOSWire) An 18-year-old biological sciences student at Carnegie Mellon University in Qatar, Al-Ansari hadn’t traveled to defend a predetermined position. Instead, she discovered that she was there to think critically, express her own viewpoint and remain open to diverse perspectives. This shift required her to navigate uncharted waters, but “I’m happy that it did,” she says. “It’s showing me the importance of sp
Matt Shafer Joins Golub Capital as Head of Golub Equity Continuation Partners14.9.2026 15:30:00 CEST | Press release
Golub Capital (“the Firm”) today announced the appointment of Matt Shafer as Managing Director and Head of the Firm’s GP-led private equity secondaries strategy, Golub Equity Continuation Partners (“GECP”). In this role, he will be responsible for leading the continued growth and development of the strategy and helping expand the Firm’s equity investment capabilities. Matt will work closely with Greg Cashman, Vice Chair and Co-Head of Golub Capital’s Sponsor Finance practice, to expand Golub Capital’s activity in this growing market. Shafer brings nearly three decades of global experience as an investor, financier and advisor working with private equity firms. He was most recently Head of Capital Solutions and U.S. Private Equity at Northleaf Capital Partners. In this role, Shafer helped lead the firm’s private equity investment activities, including secondaries, co‑investments and structured capital. Prior to Northleaf, he was Partner and Head of Americas Private Equity at Vision Capi
HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI14.9.2026 15:19:00 CEST | Press release
Investment positions AMRA to meet growing global demand for precise, scalable advanced muscle and fat imaging in clinical research and healthcare. AMRA Medical today announced an investment from HealthCap, one of Europe’s leading life science venture capital firms. This milestone marks a significant step in AMRA’s growth, underscoring market confidence in the company’s vision to transform the measurement and understanding of muscle and fat. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914838191/en/ HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI HealthCap’s backing comes as quantitative MRI gains vital importance in understanding how fat distribution and muscle composition influence disease, treatment response, and patient outcomes. Built on over 15 years of research, AMRA’s proprietary methods move beyond conventional metrics—like weight, and BMI and muscle function tests—to provide th
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum